• B Aranegui and J Jiménez-Reyes.
• Servicio de Dermatología, Hospital Universitario Infanta Cristina , Parla, Madrid, España. Electronic address: baranegui@gmail.com.
• Actas Dermosifiliogr. 2018 May 1; 109 (4): 312-322.

AbstractMorphea is an inflammatory, fibrosing skin disorder. When it occurs in childhood, it is also known as localized juvenile scleroderma. It is more common in girls and typically appears around the age of 5 to 7 years. According to a recent classification system, morphea is divided into 5 types: circumscribed (plaque), linear, generalized, pansclerotic, and mixed. Approximately 40% of patients present extracutaneous manifestations. Childhood morphea is treated with phototherapy, oral or topical calcitriol, topical tacrolimus 0.1%, methotrexate, topical or systemic corticosteroids, mycophenolate mofetil, bosentán, and topical imiquimod 5%. A variety of measuring tools are used to monitor response to treatment. Few prognostic studies have been conducted, but findings to date suggest that the disease tends to run a chronic or intermittent-recurrent course and frequently causes sequelae.Copyright © 2017 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.

37 keywords...

hide…